MARKETS / PCYN

PHARMACEUTICAL PREPARATIONS · SMALL CAP

Procyon Corp. PCYN

14 fiscal years on record · USD · FY2023 reported · SEC filings only

Revenue

$5.0M

▲ 6.4% YoY

Net income

$-341,140

Free cash flow

$-125,163

In brief

What this company does

Procyon Corporation ("Procyon" or the "Company") consolidates the operations of Procyon with AMERX® Health Care Corporation("AMERX") and Sirius Medical Supply, Inc. ("Sirius"), its wholly-owned subsidiaries, for financial purposes. AMERX® develops and markets proprietary medical products used in the treatment of pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation and other skin problems. Sirius no longer has any material operations. AMERX spent approximately $30,100 towards research and development efforts over the past fiscal year. We believe this reimbursement code is beneficial to AMERX's business, allowing customers on Medicare to seek coverage for use of these products.

Written from the business description in Procyon Corporation's annual report to the U.S. Securities and Exchange Commission, filed 25 October 2024. Every sentence was checked against that document before publication.

Growth

USD 5.0M

Revenue, FY2023 · full 14-year series below

Revenue $M Net income $M

FY2023 · Revenue 5.0 · Net income -0.3

Compound annual growth

Revenue

+1.8%

+3.5%

+5.8%

3 yrs

5 yrs

10 yrs

15 yrs

Revenue compounded at +3.5% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−7 cents

lost on every revenue dollar

Operating margin Net margin

FY2023 · Operating -4.6% · Net -6.8%

ROE

FY2023 · ROE -13.9%

Gross margin78.1%

Operating margin-4.6%

Net margin-6.8%

Return on assets-10.1%

EBITDAUSD -150,004.00

Each USD of equity lost 14 cents this year.

Cash & shareholders

—

returned in FY2023 · dividends + net buybacks

Free cash flow $

FY2023 · FCF -125163.0

Total assetsUSD 3.2M

EquityUSD 2.3M

Current ratio3.08×

Equity funds 71% of total assets.

The 14-year record

14 fiscal years

Every figure from documents filed with the SEC · USD

row low → row highnegative

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Revenue $B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Operating income $B	−0.0	−0.0	−0.0	0.0	0.0	0.0	0.0	0.0	−0.0	−0.0	0.0	−0.0	0.0	0.0
EBITDA $B	−0.0	−0.0	−0.0	0.0	0.0	0.0	0.0	0.0	−0.0	−0.0	0.0	0.0	0.0	0.0
Income tax $B	0.0	−0.0	−0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	−0.0	0.0	0.0	0.0
Net income $B	−0.0	−0.0	−0.0	0.0	0.0	0.0	−0.0	0.0	0.0	−0.0	0.0	−0.0	0.0	0.0
Free cash flow $B	−0.0	−0.0	−0.0	0.0	0.0	0.0	0.0	0.0	−0.0	−0.0	−0.0	−0.0	0.0	0.0
EPS, diluted $	−0.04	−0.01	−0.03	0.08	0.01	0.00	−0.03	0.00	0.01	−0.03	0.00	−0.02	0.01	0.02
Dividend / sh $	·	·	·	·	·	·	·	·	·	·	·	·	·	·
Payout %	·	·	·	·	·	·	·	·	·	·	·	·	·	·
ROE %	−13.9	−1.9	−7.6	27.5	5.3	1.3	−11.8	0.5	5.0	−9.6	1.0	−4.3	5.4	8.3
Shares out B	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance

Company facts, as filed

How we verify · 0 failures in 67 reconciliationsAUDITED

Reconciled in 14 of 19 fiscal years. 28 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures

ActivityPharmaceutical Preparations

Listed onnot stated in the filings

Incorporated inColorado

Fiscal year endsJune 30

SEC categorysmaller reporting company

Data on record since2010